Alkermes drug helped cut heavy drinking

Alkermes announced that updated data from its Phase III research on an experimental drug for alcoholism showed that patients switching to the drug from a placebo experienced a decline in heavy drinking. The drug developer had earlier said that the first six months of the study showed that the median number of days of heavy drinking among patients taking Vivitrex fell to three from 19 per month. This new data followed the patients over the following 12 months. At the end of that period patients reported that they had a median 1.6 days of heavy drinking per month. Heavy drinking was defined as five or more drinks per day for a man, four or more for a woman.

- read this story from for more on the trial

Suggested Articles

Biotech leaders criticized the dismissals of Chinese scientists from U.S. universities in a letter with more than 150 signatures.

In this week's EuroBiotech Report, Merck allies with Themis on vaccine R&D, Juvenescence raises $100 million and GSK files for anemia approval. 

In our EuroBiotech roundup this week, Scancell withdraws IND, Oxurion’s eye drug fails phase 2a and Abivax starts ulcerative colitis trial.